Jonathan D Licht, M.D.
UF Health Cancer Center Director And The Marshall E. Rinker Senior Chair
Department:
MD-HEMATOLOGY/ONCOLOGY-ONCOL
Business Phone:
(352) 273-8143
Business Email:
jdlicht@ufl.edu
About Jonathan D Licht
Dr. Licht is the director of the UF Health Cancer Center, holding the Marshall E. Rinker, Sr. Chair.
NCI funded for 30 years, Dr. Licht is also Principal Investigator of a Leukemia and Lymphoma Society (LLS) Specialized Center of Research. He is an Associate Editor of Oncogene and serves on the editorial boards of Cancer Discovery, Cancer Cell, Cancer Research and Clinical Cancer Research. Dr. Licht is chair of the Taskforce for Hematological Malignancies of AACR, and is co-chair of the Medical/Scientific Board of the LLS. Dr. Licht has published over 200 articles, reviews and book chapters and has mentored over 40 graduate students and postdoctoral fellows and 20 faculty members. In 2021 he was the winner of the American Society of Hematology Basic Sciences Mentor Award.
Related Links:
Teaching Profile
Courses Taught
2018
GMS7979 Advanced Research
2018
GMS7980 Research for Doctoral Dissertation
Board Certifications
-
Internal MedcineABIM
-
Medical OncologyABIM
Clinical Profile
Specialties
- Cancer
- Hematology and Oncology
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0002-3942-1369
Publications
2024
KDM6A regulates immune response genes in multiple myeloma
Blood.
144(14):1508-1520
[DOI] 10.1182/blood.2024024518.
2024
KDM6A Regulates Immune Response Genes in Multiple Myeloma.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2024.02.12.579179.
[PMID] 38405853.
2024
NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome
Blood.
144(3):283-295
[DOI] 10.1182/blood.2023022859.
2024
Recruitment of FBXO22 for targeted degradation of NSD2
Nature Chemical Biology.
[DOI] 10.1038/s41589-024-01660-y.
2024
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2024.02.24.581875.
[PMID] 38463958.
2023
Cancer incidence after asthma diagnosis: Evidence from a large clinical research network in the United States.
Cancer medicine.
12(10):11871-11877
[DOI] 10.1002/cam4.5875.
[PMID] 36999938.
2023
Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2.
Journal of the American Chemical Society.
145(14):8176-8188
[DOI] 10.1021/jacs.3c01421.
[PMID] 36976643.
2023
First-in-class multifunctional TYMS nonclassical antifolate inhibitor with potent in vivo activity that prolongs survival
JCI Insight.
8(10)
[DOI] 10.1172/jci.insight.158798.
[PMID] 37097751.
2023
Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias
Nature Cancer.
4(5):754-773
[DOI] 10.1038/s43018-023-00550-x.
[PMID] 37237081.
2023
HDAC8-mediated inhibition of EP300 drives a transcriptional state that increases melanoma brain metastasis
Nature Communications.
14(1)
[DOI] 10.1038/s41467-023-43519-1.
[PMID] 38030596.
2023
HIRA-mediated loading of histone variant H3.3 controls androgen-induced transcription by regulation of AR/BRD4 complex assembly at enhancers.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2023.05.08.536256.
[PMID] 37214820.
2023
HIRA-mediated loading of histone variant H3.3 controls androgen-induced transcription by regulation of AR/BRD4 complex assembly at enhancers.
Nucleic acids research.
51(19):10194-10217
[DOI] 10.1093/nar/gkad700.
[PMID] 37638746.
2023
Histone mutations in cancer.
Biochemical Society transactions.
51(5):1749-1763
[DOI] 10.1042/BST20210567.
[PMID] 37721138.
2023
Low muscle mass is associated with a higher risk of all–cause and cardiovascular disease–specific mortality in cancer survivors
Nutrition.
107
[DOI] 10.1016/j.nut.2022.111934.
[PMID] 36563433.
2023
Piperlongumine conjugates induce targeted protein degradation.
Cell chemical biology.
30(2):203-213.e17
[DOI] 10.1016/j.chembiol.2023.01.004.
[PMID] 36750097.
2023
Recruitment of FBXO22 for Targeted Degradation of NSD2.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2023.11.01.564830.
[PMID] 37961297.
2023
SMYD3 represses tumor-intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neck.
Cell reports.
42(7)
[DOI] 10.1016/j.celrep.2023.112823.
[PMID] 37463106.
2022
Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype
Molecular Cancer Therapeutics.
21(4):511-521
[DOI] 10.1158/1535-7163.mct-21-0216.
2022
Analysis of Biological Aging and Risks of All-Cause and Cardiovascular Disease-Specific Death in Cancer Survivors.
JAMA network open.
5(6)
[DOI] 10.1001/jamanetworkopen.2022.18183.
[PMID] 35731518.
2022
BAP1 Loss Promotes Suppressive Tumor Immune Microenvironment via Upregulation of PROS1 in Class 2 Uveal Melanomas
Cancers.
14(15)
[DOI] 10.3390/cancers14153678.
[PMID] 35954340.
2022
Cancer and aging: A call to action.
Aging and cancer.
3(2):87-94
[DOI] 10.1002/aac2.12055.
[PMID] 36188489.
2022
Cancer disparities related to poverty and rurality for 22 top cancers in Florida.
Preventive medicine reports.
29
[DOI] 10.1016/j.pmedr.2022.101922.
[PMID] 35928594.
2022
DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks
Clinical Cancer Research.
28(4):756-769
[DOI] 10.1158/1078-0432.ccr-21-2863.
2022
HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma
Cancer Gene Therapy.
29(12):1840-1846
[DOI] 10.1038/s41417-022-00452-7.
[PMID] 35332245.
2022
PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia
Cancer Discovery.
12(1):186-203
[DOI] 10.1158/2159-8290.cd-20-1771.
2021
Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia
iScience.
24(6)
[DOI] 10.1016/j.isci.2021.102651.
[PMID] 34151238.
2021
Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins.
Cell reports.
34(1)
[DOI] 10.1016/j.celrep.2020.108532.
[PMID] 33406420.
2021
Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture
Nature.
589(7841):299-305
[DOI] 10.1038/s41586-020-3017-y.
[PMID] 33299181.
2021
Leveraging epigenetics to enhance the efficacy of immunotherapy.
Clinical epigenetics.
13(1)
[DOI] 10.1186/s13148-021-01100-x.
[PMID] 34001289.
2021
Separation and Characterization of Endogenous Nucleosomes by Native Capillary Zone Electrophoresis-Top-Down Mass Spectrometry.
Analytical chemistry.
93(12):5151-5160
[DOI] 10.1021/acs.analchem.0c04975.
[PMID] 33749242.
2021
Targeting epigenetic mechanisms to overcome venetoclax resistance.
Biochimica et biophysica acta. Molecular cell research.
1868(8)
[DOI] 10.1016/j.bbamcr.2021.119047.
[PMID] 33945824.
2021
Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition
Molecular Cell.
81(10):2183-2200.e13
[DOI] 10.1016/j.molcel.2021.04.015.
[PMID] 34019788.
2021
The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma
Leukemia.
35(3):796-808
[DOI] 10.1038/s41375-020-0962-2.
[PMID] 32665698.
2021
The role of sex and rurality in cancer fatalistic beliefs and cancer screening utilization in Florida.
Cancer medicine.
10(17):6048-6057
[DOI] 10.1002/cam4.4122.
[PMID] 34254469.
2021
Widespread microRNA degradation elements in target mRNAs can assist the encoded proteins.
Genes & development.
35(23-24):1595-1609
[DOI] 10.1101/gad.348874.121.
[PMID] 34819352.
2020
Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma.
Genome research.
30(9):1217-1227
[DOI] 10.1101/gr.265520.120.
[PMID] 32820006.
2020
Decitabine limits escape from MEK inhibition in uveal melanoma.
Pigment cell & melanoma research.
33(3):507-514
[DOI] 10.1111/pcmr.12849.
[PMID] 31758842.
2020
FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML
Nature Communications.
11(1)
[DOI] 10.1038/s41467-020-14590-9.
[PMID] 32066721.
2020
High-throughput gene screen reveals modulators of nuclear shape.
Molecular biology of the cell.
31(13):1392-1402
[DOI] 10.1091/mbc.E19-09-0520.
[PMID] 32320319.
2020
Histone H3 G34 Tail Mutations in Cancer: Actions in Cis and Trans to Alter Chromatin and Gene Expression
Cancer Discovery.
10(12):1794-1796
[DOI] 10.1158/2159-8290.cd-20-1396.
2020
Oncogenesis by E2A-PBX1 in ALL: RUNX and more
Blood.
136(1):3-4
[DOI] 10.1182/blood.2020005879.
2020
Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.
Cancer letters.
475:99-108
[DOI] 10.1016/j.canlet.2020.01.040.
[PMID] 32014459.
2019
A Mutation in Histone H2B Represents a New Class of Oncogenic Driver
Cancer Discovery.
9(10):1438-1451
[DOI] 10.1158/2159-8290.cd-19-0393.
2019
An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia
Oncogene.
38(5):671-686
[DOI] 10.1038/s41388-018-0474-y.
[PMID] 30171259.
2019
Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding
Journal of Biological Chemistry.
294(33):12459-12471
[DOI] 10.1074/jbc.ra118.006159.
2019
HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma
Clinical Cancer Research.
25(18):5686-5701
[DOI] 10.1158/1078-0432.ccr-18-3382.
2019
HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy
Cancer Research.
79(11):2947-2961
[DOI] 10.1158/0008-5472.can-19-0040.
2019
Inhibition of cardiomyocyte Sprouty1 protects from cardiac ischemia-reperfusion injury.
Basic research in cardiology.
114(2)
[DOI] 10.1007/s00395-018-0713-y.
[PMID] 30635790.
2019
MYB-activated models for testing therapeutic agents in adenoid cystic carcinoma.
Oral oncology.
98:147-155
[DOI] 10.1016/j.oraloncology.2019.09.005.
[PMID] 31606723.
2019
Sprouty1 Controls Genitourinary Development via its N-Terminal Tyrosine.
Journal of the American Society of Nephrology : JASN.
30(8):1398-1411
[DOI] 10.1681/ASN.2018111085.
[PMID] 31300484.
2018
A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer.
Oncogene.
37(14):1911-1925
[DOI] 10.1038/s41388-017-0099-6.
[PMID] 29367767.
2018
CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia.
Blood.
132(8):837-848
[DOI] 10.1182/blood-2017-11-814319.
[PMID] 29760161.
2018
DISORDERED HISTONE METHYLATION IN HEMATOLOGICAL MALIGNANCIES THE CASE OF UTX/KDM6A.
Transactions of the American Clinical and Climatological Association.
129:24-36
[PMID] 30166694.
2018
Loss of Spry1 attenuates vascular smooth muscle proliferation by impairing mitogen-mediated changes in cell cycle regulatory circuits.
Journal of cellular biochemistry.
119(4):3267-3279
[DOI] 10.1002/jcb.26486.
[PMID] 29105817.
2018
Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator.
Cell reports.
25(10):2808-2820.e4
[DOI] 10.1016/j.celrep.2018.11.035.
[PMID] 30517868.
2018
Targeting Epigenetics in Cancer.
Annual review of pharmacology and toxicology.
58:187-207
[DOI] 10.1146/annurev-pharmtox-010716-105106.
[PMID] 28992434.
2018
Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity.
Epigenomes.
2(3)
[DOI] 10.3390/epigenomes2030016.
[PMID] 30761216.
2018
The nucleus is irreversibly shaped by motion of cell boundaries in cancer and non-cancer cells.
Journal of cellular physiology.
233(2):1446-1454
[DOI] 10.1002/jcp.26031.
[PMID] 28542912.
2018
USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism.
Blood.
132(4):423-434
[DOI] 10.1182/blood-2017-10-811760.
[PMID] 29844011.
2017
Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.
Current opinion in hematology.
24(4):336-344
[DOI] 10.1097/MOH.0000000000000358.
[PMID] 28441149.
2017
FQI1: a transcription-methylation switch for cancer.
Oncotarget.
8(8):12536-12537
[DOI] 10.18632/oncotarget.15087.
[PMID] 28177910.
2017
Histone H1 and Chromosomal Protein HMGN2 Regulate Prolactin-induced STAT5 Transcription Factor Recruitment and Function in Breast Cancer Cells.
The Journal of biological chemistry.
292(6):2237-2254
[DOI] 10.1074/jbc.M116.764233.
[PMID] 28035005.
2017
Sabotaging of the oxidative stress response by an oncogenic noncoding RNA.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
31(2):482-490
[DOI] 10.1096/fj.201600654R.
[PMID] 28148777.
2017
SETD2: a complex role in blood malignancy
Blood.
130(24):2576-2578
[DOI] 10.1182/blood-2017-10-811927.
[PMID] 29242204.
2017
The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.
Cold Spring Harbor perspectives in medicine.
7(6)
[DOI] 10.1101/cshperspect.a026708.
[PMID] 28193767.
2017
UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.
Cell reports.
21(3):628-640
[DOI] 10.1016/j.celrep.2017.09.078.
[PMID] 29045832.
2016
H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.
Advances in cancer research.
131:59-95
[DOI] 10.1016/bs.acr.2016.05.001.
[PMID] 27451124.
2016
Loss of Mll3 Catalytic Function Promotes Aberrant Myelopoiesis
PLOS ONE.
11(9)
[DOI] 10.1371/journal.pone.0162515.
[PMID] 27610619.
2015
Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape.
Cell reports.
12(8):1300-13
[DOI] 10.1016/j.celrep.2015.06.078.
[PMID] 26279576.
2015
DNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension.
Cell.
162(5):938-9
[DOI] 10.1016/j.cell.2015.08.005.
[PMID] 26317460.
2015
GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1.
Scientific reports.
5
[DOI] 10.1038/srep09489.
[PMID] 25807524.
2015
Post transcriptional control of the epigenetic stem cell regulator PLZF by sirtuin and HDAC deacetylases.
Epigenetics & chromatin.
8
[DOI] 10.1186/s13072-015-0030-8.
[PMID] 26405459.
2015
Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.
Leukemia & lymphoma.
56(10):2895-901
[DOI] 10.3109/10428194.2015.1006220.
[PMID] 25651430.
2015
WHSC1 promotes oncogenesis through regulation of NIMA-related kinase-7 in squamous cell carcinoma of the head and neck.
Molecular cancer research : MCR.
13(2):293-304
[DOI] 10.1158/1541-7786.MCR-14-0292-T.
[PMID] 25280969.
2014
DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.
Cell reports.
9(5):1841-1855
[DOI] 10.1016/j.celrep.2014.11.004.
[PMID] 25482556.
2014
From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma.
Cancer cell.
25(1):9-11
[DOI] 10.1016/j.ccr.2013.12.019.
[PMID] 24434206.
2014
Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.
PLoS genetics.
10(9)
[DOI] 10.1371/journal.pgen.1004566.
[PMID] 25188243.
2014
Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination.
Clinical cancer research : an official journal of the American Association for Cancer Research.
20(19):5001-8
[DOI] 10.1158/1078-0432.CCR-13-2499.
[PMID] 24987060.
2014
Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies.
Leukemia.
28(1):198-201
[DOI] 10.1038/leu.2013.204.
[PMID] 23823660.
2014
Promyelocytic leukemia zinc finger-retinoic acid receptor α (PLZF-RARα), an oncogenic transcriptional repressor of cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) and tumor protein p53 (TP53) genes.
The Journal of biological chemistry.
289(27):18641-56
[DOI] 10.1074/jbc.M113.538777.
[PMID] 24821728.
2014
Single-cell nucleosome mapping reveals the molecular basis of gene expression heterogeneity.
Proceedings of the National Academy of Sciences of the United States of America.
111(24):E2462-71
[DOI] 10.1073/pnas.1400517111.
[PMID] 24889621.
2013
A physical sciences network characterization of non-tumorigenic and metastatic cells.
Scientific reports.
3
[DOI] 10.1038/srep01449.
[PMID] 23618955.
2013
Epigenetic therapy of hematological malignancies: where are we now?
Therapeutic advances in hematology.
4(2):81-91
[DOI] 10.1177/2040620712466864.
[PMID] 23610616.
2013
Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors.
The Journal of biological chemistry.
288(33):23814-22
[DOI] 10.1074/jbc.M113.476192.
[PMID] 23814052.
2013
Expression of leukemia-associated fusion proteins increases sensitivity to histone deacetylase inhibitor-induced DNA damage and apoptosis.
Molecular cancer therapeutics.
12(8):1591-604
[DOI] 10.1158/1535-7163.MCT-12-1039.
[PMID] 23536727.
2013
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.
Cancer cell.
23(5):677-92
[DOI] 10.1016/j.ccr.2013.04.011.
[PMID] 23680150.
2013
miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation.
Leukemia.
27(2):344-52
[DOI] 10.1038/leu.2012.224.
[PMID] 22864358.
2013
Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling.
Immunity.
38(2):225-36
[DOI] 10.1016/j.immuni.2012.10.020.
[PMID] 23415911.
2013
MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC.
Leukemia.
27(3):686-94
[DOI] 10.1038/leu.2012.269.
[PMID] 22972034.
2013
Ponatinib–a step forward in overcoming resistance in chronic myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research.
19(21):5828-34
[DOI] 10.1158/1078-0432.CCR-13-0258.
[PMID] 23935038.
2013
Spry1 and Spry2 are necessary for eyelid closure.
Developmental biology.
383(2):227-38
[DOI] 10.1016/j.ydbio.2013.09.014.
[PMID] 24055172.
2013
The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer.
Oncogene.
32(23):2882-90
[DOI] 10.1038/onc.2012.297.
[PMID] 22797064.
2013
The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling.
Molecular cell.
51(2):236-48
[DOI] 10.1016/j.molcel.2013.05.003.
[PMID] 23747014.
2012
Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.
Nature medicine.
18(7):1118-22
[DOI] 10.1038/nm.2819.
[PMID] 22683780.
2012
Emerging epigenetic targets and therapies in cancer medicine.
Cancer discovery.
2(5):405-13
[DOI] 10.1158/2159-8290.CD-12-0076.
[PMID] 22588878.
2012
G Protein-regulated inducer of neurite outgrowth (GRIN) modulates Sprouty protein repression of mitogen-activated protein kinase (MAPK) activation by growth factor stimulation.
The Journal of biological chemistry.
287(17):13674-85
[DOI] 10.1074/jbc.M111.320705.
[PMID] 22383529.
2012
miR-27b controls venous specification and tip cell fate.
Blood.
119(11):2679-87
[DOI] 10.1182/blood-2011-07-370635.
[PMID] 22207734.
2012
New strategies in acute myeloid leukemia: redefining prognostic markers to guide therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research.
18(19):5163-71
[DOI] 10.1158/1078-0432.CCR-12-0313.
[PMID] 22893630.
2012
Regulation of CD4⁺ and CD8⁺ effector responses by Sprouty-1.
PloS one.
7(11)
[DOI] 10.1371/journal.pone.0049801.
[PMID] 23166773.
2012
Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses.
The Journal of biological chemistry.
287(50):42352-60
[DOI] 10.1074/jbc.M112.400721.
[PMID] 23074222.
2012
Spry1 as a novel regulator of erythropoiesis, EPO/EPOR target, and suppressor of JAK2.
Blood.
119(23):5522-31
[DOI] 10.1182/blood-2011-11-392571.
[PMID] 22508938.
2012
Total kinetic analysis reveals how combinatorial methylation patterns are established on lysines 27 and 36 of histone H3.
Proceedings of the National Academy of Sciences of the United States of America.
109(34):13549-54
[DOI] 10.1073/pnas.1205707109.
[PMID] 22869745.
2011
Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms.
Blood cancer journal.
1(11)
[DOI] 10.1038/bcj.2011.39.
[PMID] 22829077.
2011
DNMT3A mutations in acute myeloid leukemia.
Nature genetics.
43(4):289-90
[DOI] 10.1038/ng0411-289.
[PMID] 21445072.
2011
Functional characterization of Wilms tumor-suppressor WTX and tumor-associated mutants.
Oncogene.
30(7):832-42
[DOI] 10.1038/onc.2010.452.
[PMID] 20956941.
2011
MEK and MAF in myeloma therapy.
Blood.
117(8):2300-2
[DOI] 10.1182/blood-2011-01-327262.
[PMID] 21350059.
2011
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.
Blood cancer journal.
1(3)
[DOI] 10.1038/bcj.2011.4.
[PMID] 23471017.
2011
Spry1 and Spry2 are necessary for lens vesicle separation and corneal differentiation.
Investigative ophthalmology & visual science.
52(9):6887-97
[DOI] 10.1167/iovs.11-7531.
[PMID] 21743007.
2011
The 12th international conference on differentiation therapy: targeting the aberrant growth, differentiation and cell death programs of cancer cells.
Cell death and differentiation.
18(7):1231-3
[DOI] 10.1038/cdd.2010.173.
[PMID] 21212795.
2011
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.
Blood.
117(1):211-20
[DOI] 10.1182/blood-2010-07-298349.
[PMID] 20974671.
2010
Deregulation of H3K27 methylation in cancer.
Nature genetics.
42(2):100-1
[DOI] 10.1038/ng0210-100.
[PMID] 20104248.
2010
HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype.
The Journal of clinical investigation.
120(5):1535-50
[DOI] 10.1172/JCI39534.
[PMID] 20389018.
2010
Kidney development in the absence of Gdnf and Spry1 requires Fgf10.
PLoS genetics.
6(1)
[DOI] 10.1371/journal.pgen.1000809.
[PMID] 20084103.
2010
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Cancer cell.
18(6):553-67
[DOI] 10.1016/j.ccr.2010.11.015.
[PMID] 21130701.
2010
Partners in crime: Genes within an amplicon collude to globally deregulate chromatin in lymphoma.
Cancer cell.
18(6):539-41
[DOI] 10.1016/j.ccr.2010.11.032.
[PMID] 21156276.
2010
Sprouty proteins inhibit receptor-mediated activation of phosphatidylinositol-specific phospholipase C.
Molecular biology of the cell.
21(19):3487-96
[DOI] 10.1091/mbc.E10-02-0123.
[PMID] 20719962.
2010
Sprouty1 regulates reversible quiescence of a self-renewing adult muscle stem cell pool during regeneration.
Cell stem cell.
6(2):117-29
[DOI] 10.1016/j.stem.2009.12.015.
[PMID] 20144785.
2010
Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.
Clinical cancer research : an official journal of the American Association for Cancer Research.
16(17):4339-52
[DOI] 10.1158/1078-0432.CCR-10-1092.
[PMID] 20601445.
2010
Transcriptome analyses based on genetic screens for Pax3 myogenic targets in the mouse embryo.
BMC genomics.
11
[DOI] 10.1186/1471-2164-11-696.
[PMID] 21143873.
2009
Acute promyelocytic leukemia–weapons of mass differentiation.
The New England journal of medicine.
360(9):928-30
[DOI] 10.1056/NEJMcibr0810371.
[PMID] 19246367.
2009
An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1.
Proceedings of the National Academy of Sciences of the United States of America.
106(27):11154-9
[DOI] 10.1073/pnas.0901591106.
[PMID] 19549856.
2009
Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC.
Blood.
114(27):5499-511
[DOI] 10.1182/blood-2009-03-206524.
[PMID] 19855079.
2009
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.
Blood.
114(13):2764-73
[DOI] 10.1182/blood-2009-02-203547.
[PMID] 19546476.
2009
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.
Blood.
114(16):3448-58
[DOI] 10.1182/blood-2009-01-200519.
[PMID] 19652201.
2009
PLZF is a regulator of homeostatic and cytokine-induced myeloid development.
Genes & development.
23(17):2076-87
[DOI] 10.1101/gad.1788109.
[PMID] 19723763.
2009
Promyelocytic leukemia zinc finger protein regulates interferon-mediated innate immunity.
Immunity.
30(6):802-16
[DOI] 10.1016/j.immuni.2009.04.013.
[PMID] 19523849.
2009
Ret-dependent cell rearrangements in the Wolffian duct epithelium initiate ureteric bud morphogenesis.
Developmental cell.
17(2):199-209
[DOI] 10.1016/j.devcel.2009.07.013.
[PMID] 19686681.
2009
Survivin is not required for the endomitotic cell cycle of megakaryocytes.
Blood.
114(1):153-6
[DOI] 10.1182/blood-2008-11-190801.
[PMID] 19339696.
2008
A pathologic link between Wilms tumor suppressor gene, WT1, and IFI16.
Neoplasia (New York, N.Y.).
10(1):69-78
[PMID] 18231640.
2008
ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors.
Oncogene.
27(8):1045-54
[PMID] 17700520.
2008
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts.
Nature.
456(7224):980-4
[DOI] 10.1038/nature07511.
[PMID] 19043405.
2008
New molecular concepts and targets in acute myeloid leukemia.
Current opinion in hematology.
15(2):82-7
[DOI] 10.1097/MOH.0b013e3282f3ded0.
[PMID] 18300752.
2008
Retinoblastoma protein and the leukemia-associated PLZF transcription factor interact to repress target gene promoters.
Oncogene.
27(39):5260-6
[DOI] 10.1038/onc.2008.159.
[PMID] 18504436.
2008
Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells.
Blood.
112(3):644-51
[DOI] 10.1182/blood-2008-01-131813.
[PMID] 18487509.
2008
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor.
Blood.
111(6):3145-54
[PMID] 18156491.
2008
WT1 induction of mitogen-activated protein kinase phosphatase 3 represents a novel mechanism of growth suppression.
Molecular cancer research : MCR.
6(7):1225-31
[DOI] 10.1158/1541-7786.MCR-08-0078.
[PMID] 18644985.
2007
Chromatin modulation by oncogenic transcription factors: new complexity, new therapeutic targets.
Cancer cell.
11(6):475-8
[PMID] 17560329.
2007
Epigenetic regulation of normal and malignant hematopoiesis.
Oncogene.
26(47):6697-714
[PMID] 17934479.
2007
HOX deregulation in acute myeloid leukemia.
The Journal of clinical investigation.
117(4):865-8
[PMID] 17404613.
2007
Molecular characterization of acute myeloid leukemia and its impact on treatment.
Current opinion in oncology.
19(6):635-49
[PMID] 17906465.
2007
Physical and functional interactions of human endogenous retrovirus proteins Np9 and rec with the promyelocytic leukemia zinc finger protein.
Journal of virology.
81(11):5607-16
[PMID] 17360752.
2007
Sprouty2 inhibits BDNF-induced signaling and modulates neuronal differentiation and survival.
Cell death and differentiation.
14(10):1802-12
[PMID] 17599098.
2007
The PLZF gene of t (11;17)-associated APL.
Current topics in microbiology and immunology.
313:31-48
[PMID] 17217037.
2006
Branching morphogenesis of the ureteric epithelium during kidney development is coordinated by the opposing functions of GDNF and Sprouty1.
Developmental biology.
299(2):466-77
[PMID] 17022962.
2006
Computational identification of Ftz/Ftz-F1 downstream target genes.
Developmental biology.
299(1):78-90
[PMID] 16996052.
2006
Reconstructing a disease: What essential features of the retinoic acid receptor fusion oncoproteins generate acute promyelocytic leukemia?
Cancer cell.
9(2):73-4
[PMID] 16473273.
2006
Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling.
Trends in cell biology.
16(1):45-54
[PMID] 16337795.
2005
Histone acetyltransferase activity of p300 is required for transcriptional repression by the promyelocytic leukemia zinc finger protein.
Molecular and cellular biology.
25(13):5552-66
[PMID] 15964811.
2005
Over-expression of Flt3 induces NF-kappaB pathway and increases the expression of IL-6.
Leukemia research.
29(8):893-9
[PMID] 15978940.
2005
Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction.
Developmental cell.
8(2):229-39
[PMID] 15691764.
2005
Synergistic activity of Sef and Sprouty proteins in regulating the expression of Gbx2 in the mid-hindbrain region.
Genesis (New York, N.Y. : 2000).
41(3):110-5
[PMID] 15729686.
2005
The molecular pathology of acute myeloid leukemia.
Hematology. American Society of Hematology. Education Program.
137-42
[PMID] 16304371.
2005
The theoretical basis of transcriptional therapy of cancer: can it be put into practice?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
23(17):3957-70
[PMID] 15867201.
2005
Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges.
Current opinion in hematology.
12(1):7-13
[PMID] 15604885.
2005
WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak.
Cancer research.
65(18):8174-82
[PMID] 16166292.
2004
CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms’ tumors.
The American journal of pathology.
165(6):1943-53
[PMID] 15579438.
2004
Despite WT1 binding sites in the promoter region of human and mouse nucleoporin glycoprotein 210, WT1 does not influence expression of GP210.
Journal of negative results in biomedicine.
3
[PMID] 15613247.
2004
ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein.
Blood.
103(4):1454-63
[PMID] 14551142.
2004
Flt3 mutation activates p21WAF1/CIP1 gene expression through the action of STAT5.
Biochemical and biophysical research communications.
316(1):85-92
[PMID] 15003515.
2004
Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.
Nature medicine.
10(12):1329-35
[PMID] 15531890.
2004
SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
Cancer research.
64(16):5556-9
[PMID] 15313890.
2004
The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT.
Blood.
103(12):4650-8
[PMID] 14982881.
2004
Tyrosine phosphorylation of Sprouty proteins regulates their ability to inhibit growth factor signaling: a dual feedback loop.
Molecular biology of the cell.
15(5):2176-88
[PMID] 15004239.
2004
WT1 activates a glomerular-specific enhancer identified from the human nephrin gene.
Journal of the American Society of Nephrology : JASN.
15(11):2851-6
[PMID] 15504938.
2003
Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis.
Molecular and cellular biology.
23(24):8992-9002
[PMID] 14645512.
2003
BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit.
The Journal of biological chemistry.
278(29):26333-41
[PMID] 12700228.
2003
Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression.
Molecular and cellular biology.
23(24):9375-88
[PMID] 14645547.
2003
Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?
Cancer cell.
4(1):13-8
[PMID] 12892709.
2003
Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain.
Molecular cell.
12(6):1551-64
[PMID] 14690607.
2003
Molecular pathogenesis of acute promyelocytic leukaemia and APL variants.
Best practice & research. Clinical haematology.
16(3):387-408
[PMID] 12935958.
2003
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.
Nature genetics.
34(2):148-50
[PMID] 12717436.
2003
The receptor tyrosine kinase regulator Sprouty1 is a target of the tumor suppressor WT1 and important for kidney development.
The Journal of biological chemistry.
278(42):41420-30
[PMID] 12882970.
2003
Two molecular subgroups of Wilms’ tumors with or without WT1 mutations.
Clinical cancer research : an official journal of the American Association for Cancer Research.
9(6):2005-14
[PMID] 12796362.
2002
Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors.
Molecular and cellular biology.
22(6):1804-18
[PMID] 11865059.
2002
Histone deacetylases as therapeutic targets in hematologic malignancies.
Current opinion in hematology.
9(4):322-32
[PMID] 12042707.
2002
PLZF induces megakaryocytic development, activates Tpo receptor expression and interacts with GATA1 protein.
Oncogene.
21(43):6669-79
[PMID] 12242665.
2002
The effects of the Fanconi anemia zinc finger (FAZF) on cell cycle, apoptosis, and proliferation are differentiation stage-specific.
The Journal of biological chemistry.
277(29):26327-34
[PMID] 11986317.
2002
The human promyelocytic leukemia zinc finger gene is regulated by the Evi-1 oncoprotein and a novel guanine-rich site binding protein.
Leukemia.
16(9):1755-62
[PMID] 12200691.
2002
The LIM-only protein DRAL/FHL2 interacts with and is a corepressor for the promyelocytic leukemia zinc finger protein.
The Journal of biological chemistry.
277(40):37045-53
[PMID] 12145280.
2001
AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML.
Oncogene.
20(40):5660-79
[PMID] 11607817.
2001
Cloning and characterization of a novel mouse AP-2 transcription factor, AP-2delta, with unique DNA binding and transactivation properties.
The Journal of biological chemistry.
276(44):40755-60
[PMID] 11522791.
2001
Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation.
The Journal of biological chemistry.
276(49):46460-8
[PMID] 11585837.
2001
Targeting aberrant transcriptional repression in leukemia: a therapeutic reality?
The Journal of clinical investigation.
108(9):1277-8
[PMID] 11696570.
2001
The acute promyelocytic leukemia-associated protein, promyelocytic leukemia zinc finger, regulates 1,25-dihydroxyvitamin D(3)-induced monocytic differentiation of U937 cells through a physical interaction with vitamin D(3) receptor.
Blood.
98(12):3290-300
[PMID] 11719366.
2001
The HIV-1 transactivator protein Tat is a potent inducer of the human DNA repair enzyme beta-polymerase.
AIDS (London, England).
15(4):433-40
[PMID] 11242139.
2001
Translocations of the RARalpha gene in acute promyelocytic leukemia.
Oncogene.
20(49):7186-203
[PMID] 11704847.
2000
AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein.
Blood.
96(12):3939-47
[PMID] 11090081.
2000
BRCA1 physically and functionally interacts with ATF1.
The Journal of biological chemistry.
275(46):36230-7
[PMID] 10945975.
2000
E-cadherin is a WT1 target gene.
The Journal of biological chemistry.
275(15):10943-53
[PMID] 10753894.
2000
In-depth mutational analysis of the promyelocytic leukemia zinc finger BTB/POZ domain reveals motifs and residues required for biological and transcriptional functions.
Molecular and cellular biology.
20(17):6550-67
[PMID] 10938130.
2000
The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein.
Molecular and cellular biology.
20(6):2075-86
[PMID] 10688654.
1999
A novel BTB/POZ transcriptional repressor protein interacts with the Fanconi anemia group C protein and PLZF.
Blood.
94(11):3737-47
[PMID] 10572087.
1999
Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia.
Blood.
93(10):3167-215
[PMID] 10233871.
1999
Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia.
Oncogene.
18(3):633-41
[PMID] 9989813.
1999
Genomic sequence, structural organization, molecular evolution, and aberrant rearrangement of promyelocytic leukemia zinc finger gene.
Proceedings of the National Academy of Sciences of the United States of America.
96(20):11422-7
[PMID] 10500192.
1999
Genomic structure of the human PLZF gene.
Gene.
236(1):21-4
[PMID] 10433962.
1999
Identification of novel chromosomal rearrangements in acute myelogenous leukemia involving loci on chromosome 2p23, 15q22 and 17q21.
Leukemia.
13(10):1534-8
[PMID] 10516754.
1999
Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A.
Oncogene.
18(4):925-34
[PMID] 10023668.
1999
Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
Oncogene.
18(4):1113-8
[PMID] 10023688.
1999
Telomerase RNA function in recombinant Tetrahymena telomerase.
Genes & development.
13(9):1116-25
[PMID] 10323863.
1999
The promyelocytic leukemia zinc finger (PLZF) protein binds DNA in a high molecular weight complex associated with cdc2 kinase.
Nucleic acids research.
27(20):4106-13
[PMID] 10497277.
1999
Tumor-associated WT1 missense mutants indicate that transcriptional activation by WT1 is critical for growth control.
The Journal of biological chemistry.
274(19):13258-63
[PMID] 10224085.
1999
WT1 expression induces features of renal epithelial differentiation in mesenchymal fibroblasts.
Oncogene.
18(2):417-27
[PMID] 9927198.
1998
The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis.
Molecular and cellular biology.
18(9):5533-45
[PMID] 9710637.
1997
Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.
Nature.
389(6647):187-90
[PMID] 9296497.
1997
Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies.
Proceedings of the National Academy of Sciences of the United States of America.
94(19):10255-60
[PMID] 9294197.
1997
Sequence-specific DNA binding and transcriptional regulation by the promyelocytic leukemia zinc finger protein.
The Journal of biological chemistry.
272(36):22447-55
[PMID] 9278395.
1997
Transcription factors, normal myeloid development, and leukemia.
Blood.
90(2):489-519
[PMID] 9226149.
1997
Two evolutionarily conserved repression domains in the Drosophila Kruppel protein differ in activator specificity.
Molecular and cellular biology.
17(8):4820-9
[PMID] 9234738.
1997
Two N-terminal self-association domains are required for the dominant negative transcriptional activity of WT1 Denys-Drash mutant proteins.
Biochemical and biophysical research communications.
233(3):723-8
[PMID] 9168922.
1996
A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms’ tumor suppressor WT1.
Molecular and cellular biology.
16(12):6945-56
[PMID] 8943350.
1996
Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein.
Proceedings of the National Academy of Sciences of the United States of America.
93(8):3624-9
[PMID] 8622986.
1996
Reduced and altered DNA-binding and transcriptional properties of the PLZF-retinoic acid receptor-alpha chimera generated in t(11;17)-associated acute promyelocytic leukemia.
Oncogene.
12(2):323-36
[PMID] 8570209.
1996
The WT1 Wilms’ tumor suppressor gene: how much do we really know?
Biochimica et biophysica acta.
1287(1):1-28
[PMID] 8639704.
1995
Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17).
Blood.
85(4):1083-94
[PMID] 7849296.
1995
Expression of the zinc-finger gene PLZF at rhombomere boundaries in the vertebrate hindbrain.
Proceedings of the National Academy of Sciences of the United States of America.
92(6):2249-53
[PMID] 7892256.
1995
Leukemia translocation gene, PLZF, is expressed with a speckled nuclear pattern in early hematopoietic progenitors.
Blood.
86(12):4544-52
[PMID] 8541544.
1995
The transcriptional effect of WT1 is modulated by choice of expression vector.
The Journal of biological chemistry.
270(50):29976-82
[PMID] 8530399.
1995
The tumor suppressor gene WT1 inhibits ras-mediated transformation.
Oncogene.
11(4):743-50
[PMID] 7651738.
1995
WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins.
The Journal of biological chemistry.
270(18):10878-84
[PMID] 7738027.
1994
HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3.
Blood.
84(1):244-55
[PMID] 7517211.
1994
Mapping and mutagenesis of the amino-terminal transcriptional repression domain of the Drosophila Krüppel protein.
Molecular and cellular biology.
14(6):4057-66
[PMID] 8196644.
1994
Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma.
Cancer chemotherapy and pharmacology.
34(1):79-80
[PMID] 8174207.
1994
Predictive statistics and artificial intelligence in the U.S. National Cancer Institute’s Drug Discovery Program for Cancer and AIDS.
Stem cells (Dayton, Ohio).
12(1):13-22
[PMID] 8142917.
1994
Retinoic acid is required for and potentiates differentiation of acute promyelocytic leukemia cells by nonretinoid agents.
Blood.
84(7):2122-9
[PMID] 7919325.
1993
NGFIA (EGR1) contains transcription activating domains in both the amino terminal and carboxyl terminal regions of the protein.
Biochemical and biophysical research communications.
194(1):425-31
[PMID] 8392841.
1993
Selective repression of transcriptional activators at a distance by the Drosophila Krüppel protein.
Proceedings of the National Academy of Sciences of the United States of America.
90(23):11361-5
[PMID] 8248254.
1991
Phase II trial of trimetrexate in patients with advanced soft-tissue sarcoma.
Cancer chemotherapy and pharmacology.
28(3):223-5
[PMID] 1830249.
1990
Drosophila Krüppel protein is a transcriptional repressor.
Nature.
346(6279):76-9
[PMID] 2114551.
1990
Treatment of low-grade and intermediate-grade lymphoma with intensive combination chemotherapy results in long-term, disease-free survival.
Cancer.
66(4):632-9
[PMID] 1696844.
1990
Vasculitis with recurrent pulmonary hemorrhage in a long-term survivor after autologous bone marrow transplantation.
Bone marrow transplantation.
6(5):345-7
[PMID] 2291997.
1988
Gastrointestinal sarcomas.
Seminars in oncology.
15(2):181-8
[PMID] 3285480.
1986
Elevated CK-MB with normal total creatine kinase in suspected myocardial infarction: associated clinical findings and early prognosis.
American heart journal.
111(6):1041-7
[PMID] 3716977.
Grants
Oct 2024
ACTIVE
Epigenetic Mechanisms and Targeting in Hematological Malignancy
Role: Principal Investigator
Funding: LEUKEMIA & LYMPHOMA SOC
Jul 2024
ACTIVE
Enhancing Connection and Communication with Community-Based Oncology Practices to Improve Cancer Clinical Trial Recruitment: The ECCO Study
Role: Co-Investigator
Funding: LEUKEMIA & LYMPHOMA SOC
Apr 2024
ACTIVE
UF Health Cancer Center Bridge Seed Grant (Continued)
Role: Principal Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Jul 2023
ACTIVE
Exploring microRNA degradation in T-cell acute lymphoblastic leukemia
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Jul 2023
ACTIVE
Integrating Multiple Myeloma Projects to Accelerate a Cure for t(4;14) – IMMPACT
Role: Principal Investigator
Funding: IMPACTASSETS
Jun 2023
ACTIVE
UF Health Cancer Center Support Grant
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Sep 2022
ACTIVE
UF HEALTH CANCER CENTER PILOT PROJECTS GRANTS FUNDED THROUGHTHE FLORIDA CONSORTIUM OF NATIONAL CANCER INSTITUTE CENTER
Role: Principal Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Aug 2022
ACTIVE
Histone fold Mutations in Cancer Pathogenesis
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Jul 2022
– Jun 2023
Modulating Signaling Pathways in Endothelial Cells to Abate Leukemic Progression
Role: Other
Funding: LEUKEMIA & LYMPHOMA SOC
Jul 2022
ACTIVE
Defining and targeting epigenetic plasticity-driven drug resistance in melanoma
Role: Principal Investigator
Funding: H LEE MOFFITT CANCER CTR & RES INST
via NATL INST OF HLTH NCI
Jul 2022
ACTIVE
Adenylate Kinase 2-A Novel Therapeutic Target in Multiple Myeloma
Role: Principal Investigator
Funding: LEUKEMIA & LYMPHOMA SOC
Apr 2022
ACTIVE
Elucidation and targeting of epigenetic changes resulting in glucocorticoid resistance in pediatric acute lymphoblastic leukemia
Role: Principal Investigator
Funding: FL DEPT OF HLTH LIVE LIKE BELLA
Apr 2022
ACTIVE
Mitochondrial modulators of multiple myeloma growth and therapy resistance
Role: Principal Investigator
Funding: FL DEPT OF HLTH BANKHEAD-COLEY CANCER RE
Apr 2022
– Sep 2024
Florida NCI Funds – Pediatric Allocation
Role: Principal Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Jan 2022
ACTIVE
SAMUEL WAXMAN CANCER RESEARCH FOU 2022
Role: Principal Investigator
Funding: SAMUEL WAXMAN CANCER RESEARCH FOU
Jan 2022
ACTIVE
American Cancer Society Institutional Research Grant
Role: Principal Investigator
Funding: AMERICAN CANCER SOCIETY
Nov 2021
– Jun 2024
Mondello Startup Funds for Zhijian Qian
Role: Principal Investigator
Funding: UF FOUNDATION
via MONDELLO CANCER CENTER RESEARCH FUND
Nov 2021
– Mar 2024
Mondello and Davis Startup Funds for Zhijian Qian
Role: Principal Investigator
Funding: UF FOUNDATION
via JERRY W AND JUDITH S DAVIS CANCER ENDOW
Oct 2021
– Sep 2024
Investigating the Role of Adenylate Kinase 2 in Multiple Myeloma
Role: Other
Funding: LEUKEMIA & LYMPHOMA SOC
Sep 2021
– Aug 2024
DNMT3A loss facilitates KMT2C-induced enhancer switching in myeloid malignancies
Role: Principal Investigator
Funding: EVANS MEDICAL FOU
Sep 2021
– Aug 2024
UF Health Cancer Center PDX Core
Role: Principal Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Aug 2021
ACTIVE
Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis
Role: Principal Investigator
Funding: H LEE MOFFITT CANCER CTR & RES INST
via NATL INST OF HLTH NCI
Jul 2021
– Jul 2023
The mechanism of SETD2 inhibitors in NSD2 Mutant Blood Malignancies
Role: Principal Investigator
Funding: EPIZYME
Jun 2021
– Apr 2024
NSD2 Mutation as Driver of Brain Invasion in Acute Lymphoblastic Leukemia
Role: Principal Investigator
Funding: FL DEPT OF HLTH LIVE LIKE BELLA
Jun 2021
– Apr 2024
Target RNAs induce microRNA degradation in apoptotic T cell acute lymphoblastic leukemia cells
Role: Co-Investigator
Funding: FL DEPT OF HLTH LIVE LIKE BELLA
Jul 2020
– Jul 2021
Remodeling Host Immunity in Oral Cancer with Personalized RNA Nanoparticle Vaccines
Role: Other
Funding: NATL INST OF HLTH NIDCR
Mar 2020
– Jun 2020
Nuclear Dysfunction in Cancer: The Role of Mechanical Stresses Transmitted by the LINC Complex
Role: Co-Investigator
Funding: NATL INST OF HLTH NCI
Mar 2020
ACTIVE
Nuclear Dysfunction in Cancer: The Role of Mechanical Stresses Transmitted by the LINC Complex
Role: Co-Investigator
Funding: TEXAS A&M UNIV COLLEGE STATION & HSC
via NATL INST OF HLTH NCI
Oct 2019
– Sep 2024
Targeting Enhancer Dysfunction in Hematological Malignancy
Role: Principal Investigator
Funding: LEUKEMIA & LYMPHOMA SOC
Jul 2019
ACTIVE
The role of DNMT3A mutations in clonal heterogeneity and evolution of hematopoiesis
Role: Co-Investigator
Funding: NATL INST OF HLTH NIDDK
Jul 2019
– Jun 2022
UF Health Cancer Center Pilot Projects funded by UF Foundation Allocated Funds
Role: Principal Investigator
Funding: UF FOUNDATION
Jul 2019
– Dec 2021
Consequences and Vulnerabilities of NSD2 Overexpression in Multiple Myeloma
Role: Other
Funding: AMER ASSO FOR CANCER RESEARCH
Jul 2019
– Dec 2021
SWCRF Institute Without Walls
Role: Principal Investigator
Funding: SAMUEL WAXMAN CANCER RESEARCH FOU
Jul 2019
– Dec 2021
The Role of NSD2 Mutation in Therapy Resistance in Childhood Acute Lymphoblastic Leukemia
Role: Other
Funding: LEUKEMIA & LYMPHOMA SOC
Jul 2019
– Jun 2021
The role of NSD2 mutation in therapy resistance in childhood ALL
Role: Other
Funding: Rally Foundation
May 2019
– Dec 2021
Development of Diagnostic Tools for Metastatic Melanoma via Imaging of Heparanase Activity
Role: Other
Funding: US ARMY MED RES ACQUISITION
May 2019
– Apr 2020
Spatio-Temporal Organization of Chromatin and Information Transfer to Cancer
Role: Principal Investigator
Funding: NORTHWESTERN UNIV
via NATL INST OF HLTH NCI
Jul 2018
– Jun 2021
KDM6A mutation as an epigenetic driver of multiple myeloma
Role: Other
Funding: LEUKEMIA & LYMPHOMA SOC
May 2018
– Apr 2021
Identification Of Therapeutic Targets And Pathways In Relapsed Childhood Acute Lymphocytic Leukemia Associated With NSD2 Mutation
Role: Principal Investigator
Funding: FL DEPT OF HLTH
May 2018
– Apr 2021
Spatio-Temporal Organization of Chromatin and Information Transfer in Cancer//Modeling of Chromatin Biology of Cancer in Three Dimensional Models
Role: Principal Investigator
Funding: NORTHWESTERN UNIV
via NATL INST OF HLTH NCI
Apr 2018
– Mar 2021
Defining and therapeutically targeting HDAC8-driven reprogramming in melanoma brain metastasis development
Role: Principal Investigator
Funding: H LEE MOFFITT CANCER CTR & RES INST
via FL DEPT OF HLTH BANKHEAD-COLEY CANCER RE
Mar 2018
– May 2021
Leveraging CRISPR and CoMMpass data to validate genes driving high-risk MM
Role: Principal Investigator
Funding: DANA FARBER CANCER INST
via MULTIPLE MYELOMA RESEARCH FOU
Feb 2018
– Jan 2019
Targeting multiple myeloma with anti-ASCT2 agent MEDI7247
Role: Principal Investigator
Funding: MEDIMMUNE
Nov 2017
– Oct 2022
The Harry T. Mangurian, Jr. Foundation – Support for the Study of Therapy Resistant Leukemia
Role: Principal Investigator
Funding: UF FOUNDATION
via HARRY T MANGURIAN JR FOU
Sep 2017
– Jun 2021
UFHCC Triple Negative Breast Cancer (TNBC) Pilot Project Program
Role: Principal Investigator
Funding: MULTIPLE SPONSORS
Aug 2017
– Jul 2018
Targeting EZH2 in Germinal Cancer Derived B-Cell Lymphoma
Role: Principal Investigator
Funding: CORNELL UNIV
via NATL INST OF HLTH NCI
Jul 2017
– Jun 2019
Samuel Waxman Cancer Research Foundation Investigator Award
Role: Principal Investigator
Funding: SAMUEL WAXMAN CANCER RESEARCH FOU
Apr 2017
– Dec 2018
MOLECULAR TARGETS OF TRANSLOCATION T(4:14) IN MULTIPLE MYELOMA PATHOGENESIS
Role: Principal Investigator
Funding: UNIV OF IOWA
via NATL INST OF HLTH NCI
Apr 2017
– Feb 2020
Defining and targeting epigenetic deregulation in uveal melanoma
Role: Principal Investigator
Funding: H LEE MOFFITT CANCER CTR & RES INST
via FL DEPT OF HLTH BANKHEAD-COLEY CANCER RE
Apr 2017
– Jun 2017
The E1099K Mutation of NSD2 promotes Glucocorticoid Resistance in ALL
Role: Principal Investigator
Funding: LAURI STRAUSS LEUKEMIA FOU
Oct 2016
– Oct 2017
MMSET in the response to DNA Damage and Therapuetic Resistance to Hematological Malignancies
Role: Principal Investigator
Funding: CELGENE CORP
Aug 2016
– Jul 2022
The Role of MMSET in the Pathogenesis and Progression of Lymphoid Malignancy
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Aug 2016
– Jul 2017
Targeting EZH2 in Germinal Cancer Derived B-Cell Lymphoma
Role: Principal Investigator
Funding: CORNELL UNIV
via NATL INST OF HLTH NCI
Jul 2016
– Dec 2017
The Role of MMSET in Relapsed Acute Lymphocytic Leukemia
Role: Principal Investigator
Funding: ST BALDRICKS FOUNDATION
Jul 2016
– Jun 2017
Targeting Histone Methylation
Role: Principal Investigator
Funding: SAMUEL WAXMAN CANCER RESEARCH FOU
Jun 2016
– Jun 2017
Chromatin dysregulation generated by recurrent point mutation in histone methyltransferase, MMSET, drives progression of lymphoid malignancies
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Jun 2016
– Feb 2021
UTX, MLL AND PATHOGENIC DEREGULATION OF HISTONE METHYLATION IN MULTIPLE MYELOMA
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Feb 2016
– Aug 2018
SPORE in multiple myeloma
Role: Principal Investigator
Funding: DANA FARBER CANCER INST
via NATL INST OF HLTH
Jan 2016
– Dec 2021
ufhcc-ioa cancer-aging collaborative team grants
Role: Principal Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Jan 2016
– Aug 2016
MOLECULAR TARGETS OF TRANSLOCATION T(4:14) IN MULTIPLE MYELOMA PATHOGENESIS
Role: Principal Investigator
Funding: WASHINGTON UNIV SAINT LOUIS
via NATL INST OF HLTH NCI
Jan 2016
– Jun 2016
Mechanisms of resistance to chromatin targeted drugs: EZH2 inhibitors in B cell malignancies
Role: Principal Investigator
Funding: SAMUEL WAXMAN CANCER RESEARCH FOU
Oct 2015
– Apr 2021
Spatio-Temporal Organization of Chromatin and Information Transfer in Cancer
Role: Principal Investigator
Funding: NORTHWESTERN UNIV
via NATL INST OF HLTH NCI
Oct 2015
– Nov 2019
Chromatin Writers, Readers and Erasers in Multiple Myeloma
Role: Principal Investigator
Funding: MULTIPLE MYELOMA RESEARCH FOU
Oct 2015
– Sep 2018
Chromatin Mechanisms And Epigenetic Targeting In Hematological Malignancies
Role: Principal Investigator
Funding: LEUKEMIA & LYMPHOMA SOC
Oct 2015
– Jul 2016
Molecular Targets of Translocation in Multiple Myeloma
Role: Principal Investigator
Funding: NORTHWESTERN UNIV
via NATL INST OF HLTH NCI
Oct 2015
– Jun 2016
The Role of MMSET in Relapsed Acute Lymphocytic Leukemia
Role: Principal Investigator
Funding: NORTHWESTERN UNIV
via ST BALDRICKS FOUNDATION
Oct 2015
– Feb 2016
UTX, MLL AND PATHOGENIC DEREGULATION OF HISTONE METHYLATION IN MULTIPLE MYELOMA
Role: Principal Investigator
Funding: NORTHWESTERN UNIV
via NATL INST OF HLTH
Oct 2015
– Jan 2016
SPORE in Multiple Myeloma
Role: Principal Investigator
Funding: NORTHWESTERN UNIV
via NATL INST OF HLTH NCI
Jul 2015
– Jun 2024
Florida Academic Cancer Center Alliance Seed Grants
Role: Principal Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Feb 2015
– Oct 2023
UF Health Cancer Center Pilot Project Grants funded through the Florida Consortium of National Cancer Institute Centers Program
Role: Principal Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Feb 2015
– Jan 2020
UF Health Cancer Center Collaborative Cancer Related Seed Grant funded through the Florida Consortium of National Cancer Institute Centers Program
Role: Principal Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Jan 2015
– May 2024
UF Health Cancer Center Bridge Seed Grant funded through the Florida Consortium of National Cancer Institute Centers Program
Role: Principal Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Sep 2014
– Aug 2018
214 OPERATING ACCOUNT UFHCC HUMAN SUBJECT PAYMENT FUND
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Sep 2013
– Dec 2020
Chagnon Professorship – research in field of stem cell biology and bone marrow transplantation
Role: Principal Investigator
Funding: UF FOUNDATION
Sep 2012
– Jan 2018
Seed Awards and personnel appointments – Innes Professorship
Role: Principal Investigator
Funding: UF FOUNDATION
Sep 2012
– Aug 2017
Support for Oncology Nurse Education and Certification
Role: Principal Investigator
Funding: UF FOUNDATION
Feb 2012
– Jun 2022
Davis Cancer Endowment – #F014842
Role: Principal Investigator
Funding: UF FOUNDATION
Feb 2012
– Dec 2018
Support Cancer Care Coordinators and Patient Navigators
Role: Principal Investigator
Funding: UF FOUNDATION
Feb 2012
– Nov 2018
Rinker Chair – #F016150
Role: Principal Investigator
Funding: UF FOUNDATION
Feb 2012
– Mar 2018
Bronchioloalveolar (BAC) Lung Cancer Research – #F017811
Role: Principal Investigator
Funding: UF FOUNDATION
Feb 2012
– Mar 2018
Sponholtz Family Cancer Research Fund – #F14006
Role: Principal Investigator
Funding: UF FOUNDATION
Feb 2012
– Mar 2018
Support of Lymphoma Research at UF Shands Cancer Center
Role: Principal Investigator
Funding: UF FOUNDATION
Feb 2012
– Mar 2018
Women's Cancer Research – #F17801
Role: Principal Investigator
Funding: UF FOUNDATION
Aug 2011
– Mar 2018
Small Cell Cancer Equipment and Research Competition
Role: Principal Investigator
Funding: UF FOUNDATION
Jun 2010
ACTIVE
CTO-ISCT OPERATING ACCOUNTS
Role: Principal Investigator
Funding: UNIV OF FLORIDA
via UF HEALTH SHANDS HOSPITAL
Apr 2010
– Mar 2018
Medical research in the field of human cancer (male and/or female) at the College of Medicine
Role: Principal Investigator
Funding: UF FOUNDATION
Apr 2010
– Mar 2018
Prostate cancer research at UFSCC
Role: Principal Investigator
Funding: UF FOUNDATION
Jan 2008
– Mar 2018
Ocala Royal Dames Visiting Lecturship and Forum series
Role: Principal Investigator
Funding: UF FOUNDATION
Jul 2007
– May 2022
Breast Cancer Research
Role: Principal Investigator
Funding: UF FOUNDATION
Jul 2007
– Apr 2018
Salkewicz Fund for Leukemia Research
Role: Principal Investigator
Funding: UF FOUNDATION
Jul 2007
– Mar 2018
Lung Cancer Research at UFSCC
Role: Principal Investigator
Funding: UF FOUNDATION
Jul 2007
– Mar 2018
Support Cancer Research at UFSCC
Role: Principal Investigator
Funding: UF FOUNDATION
Jan 2007
– Oct 2018
Consolidated UF Shands Cancer Center Research
Role: Principal Investigator
Funding: UF FOUNDATION
Jan 2007
– Mar 2018
Pancreatic Cancer Research at UF Shands Cancer Center
Role: Principal Investigator
Funding: UF FOUNDATION
Dec 2006
– May 2018
Holloway research support for breast cancer at UFSCC
Role: Principal Investigator
Funding: UF FOUNDATION
Dec 2006
– Mar 2018
UFSCC Endowment to support cancer center research
Role: Principal Investigator
Funding: UF FOUNDATION
Dec 2006
– Nov 2017
Irwin Cancer Research at UFSCC
Role: Principal Investigator
Funding: UF FOUNDATION
Dec 2006
– Nov 2017
Krumins fund for stomach cancer research at UFSCC
Role: Principal Investigator
Funding: UF FOUNDATION
Jul 2006
– Dec 2020
21st Century Research & Economic Development Investment Program (REDIP)
Role: Project Manager
Funding: STATE UNIV SYS OF FL BOARD OF GOVERNORS
Mar 2006
– May 2023
Davis Cancer Researach Equipment
Role: Principal Investigator
Funding: UF FOUNDATION
Education
Postdoctoral Fellow- Gene Regulation
1991
·
Dana-Farber Cancer Institute
Medical Oncology
1987
·
Dana-Farber Cancer Institute
Internal Medicine
1985
·
Beth Israel Hospital, Boston MA
MD
1982
·
Columbia University College of Physicians and Surgeons
BS
1978
·
State University of New York, Stony Brook
Contact Details
Phones:
- Business:
- (352) 273-8143
Emails:
- Business:
- jdlicht@ufl.edu
Executive Assistant:
Addresses:
- Business Mailing:
-
PO Box 103633
2033 MOWRY RD STE 145
GAINESVILLE FL 32610 - Business Street:
-
2033 MOWRY RD STE 145
GAINESVILLE FL 32610